News & Publications

October 22, 2019

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to...
Read More
January 10, 2018

Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA

Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA – A Novel Treatment for Celiac Disease under Clinical Development TIMP-GLIA...
Read More
August 21, 2017

Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease

Cour Pharmaceuticals, a specialty pharma company focused on autoimmune, allergic, and inflammatory diseases, announces that its Investigational New Drug (IND)...
Read More
December 8, 2015

Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease

 Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases  Osaka, Japan, December 8, 2015,...
Read More
October 19, 2015

Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease

Proprietary Antigen-specific Nanoparticles and Cure for Celiac Disease Chicago (June 22, 2015) – Cour Pharmaceutical Development Company today announced new...
Read More